{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:03:58Z","timestamp":1792728238057,"version":"4.5.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with early-onset Alzheimer's disease (EOAD) experience seizures and subclinical epileptiform activity, which may accelerate cognitive and functional decline. Antiseizure medicines (ASMs) may be a tractable disease-modifying strategy; numerous ASMs are marketed with well-established safety. However, little information is available to guide ASM selection as few studies have rigorously quantified ASM potency and tolerability in traditional seizure models in rodents with EOAD-associated risk factors. Presenilin 2 (PSEN2) variants evoke EOAD, and these patients experience seizures. This study thus established the anticonvulsant profile of mechanistically distinct ASMs in the frontline 6-Hz limbic seizure test evoked in PSEN2-knockout (KO) mice to better inform seizure management in EOAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The median effective dose (ED50) of prototype ASMs was quantified in the 6-Hz test in male and female PSEN2-KO and wild-type (WT) C57BL\/6J mice (3\u20134 months old). Minimal motor impairment (MMI) was assessed to estimate a protective index (PI). Immunohistological detection of cFos established the extent to which 6-Hz stimulation activates discrete brain regions in KO vs. WT mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were significant genotype-related differences in the potency and tolerability of several ASMs. Valproic acid and levetiracetam were significantly more potent in male KO than in WT mice. Additionally, high doses of valproic acid significantly worsened MMI in KO mice. Conversely, carbamazepine was significantly less potent in female KO vs. WT mice. In both male and female KO mice vs. WTs, perampanel and lamotrigine were equally potent. However, there were marked genotype-related shifts in PI of both carbamazepine and perampanel, with KO mice exhibiting less MMI at the highest doses tested. Gabapentin was ineffective against 6-Hz seizures in KO mice vs. WTs without MMI changes. Neuronal activation 90 min following 6-Hz stimulation was significantly increased in the posterior parietal association cortex overlying CA1 and in the piriform cortex of WT mice, while stimulation-induced increases in cFos immunoreactivity were absent in KO mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Acute ASM potency and tolerability in the high-throughput 6-Hz test may be significantly altered with loss of normal PSEN2 function. Seizures in discrete EOAD populations may benefit from precisely selected medicines optimized for primary ASM pharmacological mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1223472","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:57:05Z","timestamp":1690887425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Loss of normal Alzheimer's disease-associated Presenilin 2 function alters antiseizure medicine potency and tolerability in the 6-Hz focal seizure model"],"prefix":"10.3389","volume":"14","author":[{"given":"Leanne M.","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barker-Haliski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/jamaneurol.2013.136","article-title":"Seizures and epileptiform activity in the early stages of Alzheimer disease","volume":"70","author":"Vossel","year":"2013","journal-title":"J Am Med Assoc Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/JAD-170031","article-title":"Relative incidence of seizures and myoclonus in Alzheimer's disease, dementia with lewy bodies, and frontotemporal dementia","volume":"60","author":"Beagle","year":"2017","journal-title":"J Alzheimers Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/WNL.0000000000003048","article-title":"Seizures in dominantly inherited Alzheimer disease","volume":"87","author":"Zarea","year":"2016","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1528-1167.2006.00554.x","article-title":"Incidence and predictors of seizures in patients with Alzheimer's disease","volume":"47","author":"Amatniek","year":"2006","journal-title":"Epilepsia."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/brain\/awq033","article-title":"Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2","volume":"133","author":"Jayadev","year":"2010","journal-title":"Brain."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1007\/s11064-021-03332-y","article-title":"Alzheimer's disease and epilepsy: a perspective on the opportunities for overlapping therapeutic innovation","volume":"21","author":"Lehmann","year":"2021","journal-title":"Neurochem Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eplepsyres.2011.01.003","article-title":"Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels","volume":"94","author":"Ziyatdinova","year":"2011","journal-title":"Epilepsy Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/epi.12993","article-title":"A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizure-associated death","volume":"56","author":"Chan","year":"2015","journal-title":"Epilepsia."},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2015.02.005","article-title":"Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer's disease is not long-lasting after treatment discontinuation","volume":"112","author":"Ziyatdinova","year":"2015","journal-title":"Epilepsy Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2174\/1567205013666160129095508","article-title":"Increased epileptiform EEG activity and decreased seizure threshold in arctic APP transgenic mouse model of Alzheimer's disease","volume":"13","author":"Ziyatdinova","year":"2016","journal-title":"Curr Alzheimer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"104719","DOI":"10.1016\/j.nbd.2019.104719","article-title":"Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition","volume":"136","author":"Beckman","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"17355","DOI":"10.1111\/epi.17355","article-title":"Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease","volume":"2022","author":"Vande Vyver","year":"2022","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114321","DOI":"10.1016\/j.expneurol.2023.114321","article-title":"Chronic seizures induce sex-specific cognitive deficits with loss of presenilin 2 function","volume":"361","author":"Knox","year":"2023","journal-title":"Exp Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ana.24794","article-title":"Incidence and impact of subclinical epileptiform activity in Alzheimer's disease","volume":"80","author":"Vossel","year":"2016","journal-title":"Ann Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.clinph.2021.03.050","article-title":"Subclinical epileptiform activity accelerates the progression of Alzheimer's disease: a long-term EEG study","volume":"132","author":"Horvath","year":"2021","journal-title":"Clin Neurophysiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","article-title":"Epileptic activity in Alzheimer's disease: causes and clinical relevance","volume":"16","author":"Vossel","year":"2017","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm.4330","article-title":"Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease","volume":"23","author":"Lam","year":"2017","journal-title":"Nat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2259","DOI":"10.1212\/WNL.0000000000010612","article-title":"Association of epileptiform abnormalities and seizures in Alzheimer disease","volume":"95","author":"Lam","year":"2020","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.yebeh.2010.01.015","article-title":"Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease","volume":"17","author":"Cumbo","year":"2010","journal-title":"Epilepsy Behav."},{"key":"B20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron."},{"key":"B21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s13063-021-05404-4","article-title":"An investigation of levetiracetam in Alzheimer's disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study","volume":"22","author":"Sen","year":"2021","journal-title":"Trials."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with Alzheimer's disease with and without epileptiform activity: a randomized clinical trial","volume":"78","author":"Vossel","year":"2021","journal-title":"J Am Med Assoc Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1471-4159.2005.03266.x","article-title":"Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment","volume":"94","author":"Wiley","year":"2005","journal-title":"J Neurochem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"a006304","DOI":"10.1101\/cshperspect.a006304","article-title":"Presenilins and gamma-secretase: structure, function, and role in Alzheimer's disease","volume":"2","author":"De Strooper","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e15743","DOI":"10.1371\/journal.pone.0015743","article-title":"Presenilin 2 is the predominant gamma-secretase in microglia and modulates cytokine release","volume":"5","author":"Jayadev","year":"2010","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jnc.12400","article-title":"Presenilin 2 influences miR146 level and activity in microglia","volume":"127","author":"Jayadev","year":"2013","journal-title":"J Neurochem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3233\/JAD-200492","article-title":"Early-onset familial Alzheimer's disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype","volume":"77","author":"Fung","year":"2020","journal-title":"J Alzheimer's Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.embor.7400897","article-title":"Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease","volume":"8","author":"De Strooper","year":"2007","journal-title":"EMBO Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"15132","DOI":"10.18632\/oncotarget.23738","article-title":"The genes associated with early-onset Alzheimer's disease","volume":"9","author":"Dai","year":"2018","journal-title":"Oncotarget."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1523\/JNEUROSCI.0297-22.2022","article-title":"Presenilin and APP regulate synaptic kainate receptors","volume":"42","author":"Barthet","year":"2022","journal-title":"J Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.devcel.2022.05.006","article-title":"gamma-secretase promotes Drosophila postsynaptic development through the cleavage of a Wnt receptor","volume":"57","author":"Restrepo","year":"2022","journal-title":"Dev Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron."},{"key":"B33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/archneurol.2009.15","article-title":"Epilepsy and cognitive impairments in Alzheimer's disease","volume":"66","author":"Palop","year":"2009","journal-title":"Arch Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"Loscher","year":"2016","journal-title":"Epilepsy Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","article-title":"Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs","volume":"42","author":"Loscher","year":"2017","journal-title":"Neurochem Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"107750","DOI":"10.1016\/j.neuropharm.2019.107750","article-title":"Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening","volume":"2019","author":"Barker-Haliski","year":"2019","journal-title":"Neuropharmacology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","article-title":"Epilepsy in older people","volume":"395","author":"Sen","year":"2020","journal-title":"Lancet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5698\/1535-7511-16.3.182","article-title":"2014 epilepsy benchmarks area I: understanding the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic conditions","volume":"16","author":"Caplan","year":"2016","journal-title":"Epilepsy Curr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5698\/1535-7511-16.3.192","article-title":"2014 epilepsy benchmarks area III: improve treatment options for controlling seizures and epilepsy-related conditions without side effects","volume":"16","author":"Dlugos","year":"2016","journal-title":"Epilepsy Curr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1007\/s11064-017-2227-7","article-title":"Validation of a preclinical drug screening platform for pharmacoresistant epilepsy","volume":"42","author":"Barker-Haliski","year":"2017","journal-title":"Neurochem Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/epi.16925","article-title":"Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program","volume":"62","author":"Pernici","year":"2021","journal-title":"Epilepsia."},{"key":"B43","doi-asserted-by":"publisher","first-page":"114288","DOI":"10.1016\/j.expneurol.2022.114288","article-title":"Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery","volume":"360","author":"Del Pozo","year":"2023","journal-title":"Exp Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.eplepsyres.2015.06.003","article-title":"Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds","volume":"115","author":"Walrave","year":"2015","journal-title":"Epilepsy Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/epi4.12254","article-title":"A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A report of the TASK3 pharmacology working group of the ILAE\/AES joint translational task force","volume":"3","author":"Barker-Haliski","year":"2018","journal-title":"Epilepsia Open."},{"key":"B47","doi-asserted-by":"publisher","first-page":"107811","DOI":"10.1016\/j.neuropharm.2019.107811","article-title":"The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy","volume":"166","author":"Wilcox","year":"2020","journal-title":"Neuropharmacology."},{"key":"B48","doi-asserted-by":"publisher","first-page":"16624","DOI":"10.1111\/epi.16624","article-title":"Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred versus inbred mice","volume":"2020","author":"Koneval","year":"2020","journal-title":"Epilepsia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"11872","DOI":"10.1073\/pnas.96.21.11872","article-title":"Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency","volume":"96","author":"Herreman","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B50","doi-asserted-by":"publisher","first-page":"257261","DOI":"10.1124\/jpet.119.257261","article-title":"Repeated intraperitoneal administration of low-concentration methylcellulose leads to systemic histologic lesions without loss of preclinical phenotype","volume":"119","author":"Meeker","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/epi.14190","article-title":"Lamotrigine-resistant corneal-kindled mice: a model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery","volume":"59","author":"Koneval","year":"2018","journal-title":"Epilepsia."},{"key":"B52","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jps.3030460322","article-title":"A note on a simple apparatus for detecting neurological deficit in rats and mice","volume":"46","author":"Dunham","year":"1957","journal-title":"J Amer Pharm Ass Sci Ed."},{"key":"B53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archinte.1997.00440270035003","article-title":"Seizures and epilepsy in the elderly","volume":"157","author":"Thomas","year":"1997","journal-title":"Arch Intern Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/17425255.2020.1806236","article-title":"Pharmacokinetic considerations about antiseizure medications in the elderly","volume":"16","author":"Roberti","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1006\/frne.1993.1006","article-title":"c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems","volume":"14","author":"Hoffman","year":"1993","journal-title":"Front Neuroendocrinol."},{"key":"B56","volume-title":"Probit Analysis. A Statistical Treatment of the Sigmoid Response Curve","author":"Finney","year":"1952"},{"key":"B57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1126\/science.79.2037.38","article-title":"The method of probits","volume":"79","author":"Bliss","year":"1934","journal-title":"Science."},{"key":"B58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3238\/arztebl.2009.0335","article-title":"Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications","volume":"106","author":"Du Prel","year":"2009","journal-title":"Dtsch Arztebl Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(00)04522-0","article-title":"Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours","volume":"357","author":"Shakespeare","year":"2001","journal-title":"Lancet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/epi.16718","article-title":"Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action?","volume":"61","author":"Guignet","year":"2020","journal-title":"Epilepsia."},{"key":"B62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5698\/1535-7511-16.3.198","article-title":"2014 epilepsy benchmarks area IV: limit or prevent adverse consequence of seizures and their treatment across the lifespan","volume":"16","author":"Goldman","year":"2016","journal-title":"Epilepsy Curr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eplepsyres.2017.05.002","article-title":"Efficacy of anticonvulsant substances in the 6Hz seizure test: comparison of two rodent species","volume":"134","author":"Esneault","year":"2017","journal-title":"Epilepsy Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.yebeh.2017.05.040","article-title":"The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy","volume":"73","author":"Loscher","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0234070","DOI":"10.1371\/journal.pone.0234070","article-title":"Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice","volume":"15","author":"Luszczki","year":"2020","journal-title":"PLoS ONE."},{"key":"B66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","article-title":"Restricted location of PSEN2\/gamma-secretase determines substrate specificity and generates an intracellular abeta pool","volume":"166","author":"Sannerud","year":"2016","journal-title":"Cell."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s11064-017-2275-z","article-title":"The national institute of neurological disorders and stroke (NINDS) epilepsy therapy screening program (ETSP)","volume":"17","author":"Kehne","year":"2017","journal-title":"Neurochem Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/epi.17462","article-title":"High-frequency oscillations (250\u2013500 Hz) in animal models of Alzheimer's disease and two animal models of epilepsy","volume":"64","author":"Lisgaras","year":"2023","journal-title":"Epilepsia."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch Gen Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0035-3787(06)75098-6","article-title":"Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology","volume":"162","author":"Muyllaert","year":"2006","journal-title":"Rev Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2013.11.014","article-title":"Antisense oligonucleotide against GSK-3beta in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease","volume":"67","author":"Farr","year":"2014","journal-title":"Free Radic Biol Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1468-1331.2007.01907.x","article-title":"Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study","volume":"14","author":"Belcastro","year":"2007","journal-title":"Eur J Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"13943","DOI":"10.1111\/epi.13943","article-title":"6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain","volume":"2017","author":"Albertini","year":"2017","journal-title":"Epilepsia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bcp.15532","article-title":"Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer's Coordinating Center (2006-2019)","volume":"89","author":"Oh","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ceca.2006.03.002","article-title":"Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels","volume":"39","author":"Zatti","year":"2006","journal-title":"Cell Calcium."},{"key":"B77","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update","volume":"52","author":"Italiano","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"B78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bcp.13400","article-title":"Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children","volume":"84","author":"Van Dijkman","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"11760","DOI":"10.1523\/JNEUROSCI.3864-08.2008","article-title":"The immediate early gene arc\/arg3.1: regulation, mechanisms, and function","volume":"28","author":"Bramham","year":"2008","journal-title":"J Neurosci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.conb.2011.12.006","article-title":"Regulation of AMPA receptor trafficking and synaptic plasticity","volume":"22","author":"Anggono","year":"2012","journal-title":"Curr Opin Neurobiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.neuron.2006.10.035","article-title":"AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss","volume":"52","author":"Hsieh","year":"2006","journal-title":"Neuron."},{"key":"B82","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3233\/JAD-2010-091654","article-title":"Amyloid-beta decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2","volume":"21","author":"Liu","year":"2010","journal-title":"J Alzheimer's Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1038\/srep10934","article-title":"Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus","volume":"5","author":"Whitcomb","year":"2015","journal-title":"Sci Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neurobiolaging.2016.08.025","article-title":"Epilepsy, amyloid-beta, and D1 dopamine receptors: a possible pathogenetic link?","volume":"48","author":"Costa","year":"2016","journal-title":"Neurobiol Aging."},{"key":"B85","doi-asserted-by":"publisher","first-page":"93","DOI":"10.14581\/jer.21012","article-title":"A severe dementia case in end of life care with psychiatric symptoms treated by perampanel","volume":"11","author":"Kumamoto","year":"2021","journal-title":"J Epilepsy Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.seizure.2021.12.001","article-title":"The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy","volume":"94","author":"Witt","year":"2022","journal-title":"Seizure."},{"key":"B87","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fneur.2014.00259","article-title":"The piriform cortex and human focal epilepsy","volume":"5","author":"Vaughan","year":"2014","journal-title":"Front Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1528-1167.2008.01507.x","article-title":"Mapping seizure pathways in the temporal lobe","volume":"49","author":"Mcintyre","year":"2008","journal-title":"Epilepsia."},{"key":"B89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0006-8993(00)02730-X","article-title":"Temporal changes in neuronal dropout following inductions of lithium\/pilocarpine seizures in the rat","volume":"881","author":"Peredery","year":"2000","journal-title":"Brain Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1528-1157.2002.11301.x","article-title":"Magnetic resonance imaging in the study of the lithium-pilocarpine model of temporal lobe epilepsy in adult rats","volume":"43","author":"Roch","year":"2002","journal-title":"Epilepsia."},{"key":"B91","doi-asserted-by":"publisher","first-page":"26274","DOI":"10.1002\/hbm.26274","article-title":"Automatic and manual segmentation of the piriform cortex: method development and validation in patients with temporal lobe epilepsy and Alzheimer's disease","volume":"2023","author":"Steinbart","year":"2023","journal-title":"Hum Brain Mapp"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/epi.13764","article-title":"Development and pharmacologic characterization of the rat 6 Hz model of partial seizures","volume":"58","author":"Metcalf","year":"2017","journal-title":"Epilepsia."},{"key":"B93","doi-asserted-by":"publisher","first-page":"833624","DOI":"10.3389\/fneur.2022.833624","article-title":"Can old animals reveal new targets? The aging and degenerating brain as a new precision medicine opportunity for epilepsy","volume":"13","author":"Del Pozo","year":"2022","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1223472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T10:57:11Z","timestamp":1690887431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1223472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":93,"alternative-id":["10.3389\/fneur.2023.1223472"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1223472","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"article-number":"1223472"}}